Search alternatives:
nm decrease » nn decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
30 decrease » nn decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decreased (Expand Search), _ decreases (Expand Search)
_ decrease » _ decreased (Expand Search)
12 nm » 10 nm (Expand Search), 12 mm (Expand Search), 12 m (Expand Search)
_ 30 » _ 3 (Expand Search), _ 10 (Expand Search), _ 3d (Expand Search)
Showing 1 - 20 results of 50,096 for search '(((( 59 ((a decrease) OR (_ decrease)) ) OR ( 12 nm decrease ))) OR ( _ 30 decrease ))*', query time: 0.88s Refine Results
  1. 1
    Ifit2 deficiency results in decreased neuroinflammation upon RSA59 infection.

    Ifit2 deficiency results in decreased neuroinflammation upon RSA59 infection. by Jayasri Das Sarma (652473)

    Published 2020
    Save to List
    Saved in:
  2. 2
    HRMECs treated with SUZ12 siRNA demonstrate increased miR-200b expression, decreased VEGF expression and decreased endothelial branching.

    HRMECs treated with SUZ12 siRNA demonstrate increased miR-200b expression, decreased VEGF expression and decreased endothelial branching. by Michael Anthony Ruiz (726055)

    Published 2015
    “…[NG+control siRNA = 5mM D-glucose + 100nM control siRNA, HG+control siRNA = 25mM D-glucose + 100nM control siRNA, HG+EZH2 siRNA = 25mM D-glucose + 100nM EZH2 siRNA, HG+SUZ12 siRNA = 25mM + 100nM SUZ12 siRNA; identical letters represent groups that are not significantly different; p < 0.05; n = 6; data expressed as mean ± SEM, normalized to U6 or β-actin and expressed as a fold change of NG+control siRNA].…”
    Save to List
    Saved in:
  3. 3
    Decreased number of anastomoses in BCAS-treated mice.

    Decreased number of anastomoses in BCAS-treated mice. by Jill M. Roberts (4760685)

    Published 2018
    Save to List
    Saved in:
  4. 4
    VPS34 inhibition decreases intracellular levels of cholesteryl-esters, blocks cholesterol uptake and enhances lysosomal degradation of LDLR.

    VPS34 inhibition decreases intracellular levels of cholesteryl-esters, blocks cholesterol uptake and enhances lysosomal degradation of LDLR. by Marek J. Kobylarz (9292599)

    Published 2020
    Save to List
    Saved in:
  5. 5
    Triclabendazole decreases intracellular cAMP.

    Triclabendazole decreases intracellular cAMP. by Yong Joo Lee (357685)

    Published 2013
    Save to List
    Saved in:
  6. 6
    Over time, melanization decreases with aging, higher temperature, and infection.

    Over time, melanization decreases with aging, higher temperature, and infection. by Lindsay E. Martin (17377067)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  7. 7
    Decrease of myopia progression with 0.025% atropine

    Decrease of myopia progression with 0.025% atropine by Celso Marcelo da Cunha (4894324)

    Published 2018
    “…Results: Of the 60 children, the 30 in group 1 had an age mean and SD 8.21 +/- 1.72, and of the control group were 8.17 +/- 1.73 years. …”
    Save to List
    Saved in:
  8. 8
    Silencing of MCT4 decreases cell proliferation.

    Silencing of MCT4 decreases cell proliferation. by Jiang Zhu (40858)

    Published 2014
    Save to List
    Saved in:
  9. 9
    Cellular iron depletion decreases frataxin expression.

    Cellular iron depletion decreases frataxin expression. by Kuanyu Li (126061)

    Published 2013
    “…<p>(A) Iron depletion decreases frataxin and TFAP2 mRNA levels in tested cells. qRT-PCR was performed to quantify the mRNA levels of frataxin, SRF, and TFAP2 in SHSY5Y and HEK293 cells following treatment with 30 µM DFO for 48 hours. …”
    Save to List
    Saved in:
  10. 10
    Ifit2 deficiency decreases CX3CR1 expression in microglia following infection.

    Ifit2 deficiency decreases CX3CR1 expression in microglia following infection. by Jayasri Das Sarma (652473)

    Published 2020
    Save to List
    Saved in:
  11. 11
    Rapamycin treatment significantly decreases induction of lytic KSHV proteins.

    Rapamycin treatment significantly decreases induction of lytic KSHV proteins. by Lisa A. Nichols (357612)

    Published 2013
    Save to List
    Saved in:
  12. 12
    Characterization of the optimized nanoparticles (These values are means of a minimum of 5 batches).

    Characterization of the optimized nanoparticles (These values are means of a minimum of 5 batches). by Anjuman Arora (750291)

    Published 2015
    Subjects:
    Save to List
    Saved in:
  13. 13
    TEM images of (a) amlodipine (b) hydrochlorothiazide and (c) candesartan nanoparticles.

    TEM images of (a) amlodipine (b) hydrochlorothiazide and (c) candesartan nanoparticles. by Anjuman Arora (750291)

    Published 2015
    Subjects:
    Save to List
    Saved in:
  14. 14
    (A) Decreased ENA levels triggers progressive degeneration in the optic lobe.

    (A) Decreased ENA levels triggers progressive degeneration in the optic lobe. by Carolina Rezával (270700)

    Published 2008
    “…The s-LNvs showed a small but significant decrease in the number of PDF positive neurons (* <i>p</i><0.05). …”
    Save to List
    Saved in:
  15. 15
    UGGT activity decreases in <i>uggt-1(RNAi)</i> worms but no decrease was observed in <i>uggt-2 (RNAi)</i> worms.

    UGGT activity decreases in <i>uggt-1(RNAi)</i> worms but no decrease was observed in <i>uggt-2 (RNAi)</i> worms. by Lucila I. Buzzi (198284)

    Published 2011
    Save to List
    Saved in:
  16. 16
    Knocking down of TRIM59 decreased the expression of cell cycle proteins.

    Knocking down of TRIM59 decreased the expression of cell cycle proteins. by Weihua Zhan (830500)

    Published 2015
    Save to List
    Saved in:
  17. 17
    FT-IR spectra of (a) amlodipine (b) hydrochlorohiazide and (c) candesartan nanoparticles.

    FT-IR spectra of (a) amlodipine (b) hydrochlorohiazide and (c) candesartan nanoparticles. by Anjuman Arora (750291)

    Published 2015
    Subjects:
    Save to List
    Saved in:
  18. 18
    PK profile of: (a) The developed NanoFDC and (b) Combination of the free candidate drugs.

    PK profile of: (a) The developed NanoFDC and (b) Combination of the free candidate drugs. by Anjuman Arora (750291)

    Published 2015
    Subjects:
    Save to List
    Saved in:
  19. 19
    <i>In-vitro</i> drug release profiles of (a) amlodipine, (b) hydrochlorothiazide, and (c) candesartan.

    <i>In-vitro</i> drug release profiles of (a) amlodipine, (b) hydrochlorothiazide, and (c) candesartan. by Anjuman Arora (750291)

    Published 2015
    Subjects:
    Save to List
    Saved in:
  20. 20
    PK profiles of the developed nanoparticles vs. free drugs in rats (a) amlodipine, (b) hydrochlorothiazide, and (c) candesartan.

    PK profiles of the developed nanoparticles vs. free drugs in rats (a) amlodipine, (b) hydrochlorothiazide, and (c) candesartan. by Anjuman Arora (750291)

    Published 2015
    Subjects:
    Save to List
    Saved in:

Search Tools: